A man working on construction for this November’s Formula 1 Las Vegas Grand Prix has tragically died after suffering a “major laceration to the neck.” The Las Vegas Metropolitan Police Department were called to the Bellagio Fountains area on Saturday morning – at around 11:30am – after a worker was injured. The man, whose age has not been released, was transported to a local hospital but was later pronounced dead, as reported by ABC News. A spokesperson for the police confirmed the worker was involved in construction for the Las Vegas race circuit. The grand prix weekend is being held on the iconic Strip on 16-18 November. Further details are yet to be made public. The Occupational Safety and Health Administration will investigate the incident, police said. The Independent has contacted the Las Vegas Metropolitan Police Department and Formula 1 for further comment. Preparation for the Las Vegas race has seen numerous roads closed while construction takes place, with the project as a whole costing an estimated $560m. The 3.8-mile track passes a host of famous Sin City landmarks, including the Bellagio, Caesars Palace and the new MGM Sphere. F1 is returning to Vegas for the first time since 1982, when the Caesars Palace Grand Prix was held in the car park of the famous hotel. The race takes place at 10pm local time (6am GMT) on Saturday 18 November. Read More The rise of Oscar Piastri: A genuine rival for Lando Norris at last ‘Shocker of a race’: Christian Horner pulls apart Sergio Perez’s display in Japan Christian Horner reveals Max Verstappen ambition ahead of Japan victory

After navigating the daunting challenges to access the treatment she needed, Tescha Hawley started the Day Eagle Hope Project to help other Native American cancer patients. Today, her organization is addressing gaps in health care and nutrition for thousands on her reservation.

DURHAM, N.C.--(BUSINESS WIRE)--Jul 11, 2023--

NEW YORK--(BUSINESS WIRE)--Jul 27, 2023--

Greek authorities say some 19,000 people have been evacuated from the Greek island of Rhodes as wildfires continue burning for a sixth day on three fronts

A new survey has found that nearly half of adults in the United States are interested in taking prescription drugs for weight loss, such as Ozempic or Wegovy. In a KFF health tracking poll published on 3 August, researchers reported that 45 per cent of adults said they’d be interested in taking a “safe and effective” prescription drug for weight loss. Meanwhile, seven in 10 adults said they’ve heard at least “a little” about a new class of drugs being used for weight loss, with about one in five saying they have heard “a lot” about these drugs. Ozempic is a type 2 diabetes medication known for its weight loss side effects. Similar semaglutide injections, such as Wegovy and Mounjaro, have been specifically approved for the treatment of obesity and weight loss. This class of drugs called GLP-1 agonists works by mimicking a hormone called glucagon-like peptide 1 (GLP-1), regulating blood sugar levels and slowing down the rate at which food leaves the stomach to create the feeling of fullness. Of the US adults surveyed, older groups were some of the most aware of prescription weight loss drugs, with 76 per cent being those who have been told by a doctor in the past five years that they are overweight or obese. Nearly 60 per cent of those surveyed said they were currently trying to lose weight as well. While there was an overall interest in taking a prescription weight loss drug, that interest significantly decreased when people were asked whether they would take the medication as a routine injection. Only 16 per cent of adults said they would still take Ozempic or Wegovy, even if it wasn’t covered by their health insurance and was not specifically approved by the US Food and Drug Administration for weight loss. In fact, most people believed that insurance companies should cover the cost of weight loss drugs for adults who are overweight or obese, with an overwhelming 80 per cent of adults. Additionally, a large majority of adults believed the substantial profits that pharmaceutical companies have made from increased demand for weight loss drugs is a major factor contributing to the cost of injections like Ozempic and Wegovy. According to Novo Nordisk, the pharmaceutical company behind these prescription drugs for diabetes and weight loss, the list price for Ozempic can cost $935.77 per month without health insurance. Although the majority of adults said they trust pharmaceutical companies like Novo Nordisk to provide “reliable information” about safety and side effects of GLP-1 agonists, only 22 per cent said they trust these companies to price their products fairly. The FDA has listed the most common side effects of taking Wegovy as nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, indigestion, dizziness, and digestive disorders. More serious complications can occur from use of Wegovy or Mounjaro, such as the “potential risk of thyroid C-cell tumours,” pancreatitis, gallbladder problems, acute kidney injury, increased heart rate, and suicidal behaviour or thinking. Taking Ozempic can also lead to possible thyroid tumours, including cancer, pancreatitis, changes in vision, and kidney and gallbladder problems. Recently, several patients reported suffering from severe gastroparesis, also known as stomach paralysis, after taking the prescription weight loss medications. In a report from CNN, two people claimed that their “stomachs are paralysed” after taking Ozempic. “I wish I never touched it. I wish I’d never heard of it in my life,” Joanie Knight, a 37-year-old from Louisiana, told CNN. “This medicine made my life hell. So much hell. It has cost me money. It cost me a lot of stress; it cost me days and nights and trips with my family. It’s cost me a lot, and it’s not worth it. The price is too high.” One woman was also diagnosed with cyclic vomiting syndrome, which causes her to throw up multiple times a day. “I’ve almost been off Ozempic for a year, but I’m still not back to my normal,” said Emily Wright, a 38-year-old teacher from Toronto. Shortly after the report, the FDA shared in a statement with The Independent that it has become aware of stomach paralysis occurring among patients taking the medications. “The FDA has received reports of gastroparesis with semaglutide and liraglutide, of which some documented the adverse event as not recovered after discontinuation of the respective product at the time of the report,” the agency said. However, officials clarified that they were unable to determine whether taking Ozempic or Wegovy was the cause of stomach paralysis, or if it was caused by a different issue. “Gastroparesis can be a complication of diabetes that is related to long-standing or poorly controlled disease, further complicating the ability to determine what role the drugs played in the reported events,” the FDA added. In response to reports of stomach paralysis, drug manufacturer Novo Nordisk noted that these medications have been used to treat type 2 diabetes “for more than 15 years”, and for the “treatment of obesity” for eight years. “Semaglutide has been extensively examined in robust clinical development programs, large real world evidence studies and has cumulatively over 9.5 million patient years of exposure,” a spokesperson for Novo Nordisk said in a statement to The Independent. “Gastrointestinal (GI) events are well-known side effects of the GLP-1 class. For semaglutide, the majority of GI side effects are mild to moderate in severity and of short duration. GLP-1’s are known to cause a delay in gastric emptying, as noted in the label of each of our GLP-1 RA medications. Symptoms of delayed gastric emptying, nausea and vomiting are listed as side effects.” Read More Obese people on weight-loss jabs ‘should be prepared to stay on them for life’ Ozempic users report stomach paralysis as weight loss drug side effect: ‘I wish I never touched it’ Sharon Osbourne says she was ‘nauseous’ for weeks after taking Ozempic to lose weight Sharon Osbourne reveals what Ozempic did to her when she was taking it Ozempic users report stomach paralysis as side effect: ‘I wish I never touched it’ Lorraine Candy: ‘Perimenopausal rage made me unravel’

Twitter has launched yet another new feature in order to promote its fledgling paid subscription

KATHMANDU, Nepal (AP) — Thousands of farmers and their families across Nepal celebrated an annual paddy festival by planting rice, splashing in the muddy fields and enjoying a special feast.

A strong, unique password for every account is a must in the age of constant

The introduction of multichannel soundbars in the late 1990s was a seismic shift in the

LINCOLN, Neb.--(BUSINESS WIRE)--Aug 9, 2023--

PALO ALTO, Calif.--(BUSINESS WIRE)--Jul 26, 2023--